RxDoctor Payments Data

Arash Tirandaz, MD

Internal Medicine · Plano, TXNPI 1790723245

Payments from drug & device makers

$7,444in general payments, 2019–2025

Across 453 payments — averaging $16.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • Amgen$1K
  • AbbVie$538
  • Astellas Pharma US Inc$442
  • GSK$418
  • AstraZeneca$400
  • plus $3K from 36 others

What the payments were for

  • Food & beverage$7,11796%
  • Education$3104%
  • Entertainment$180%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,444 in reported general payments places this provider in the 90th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$386,044
Medicare patients
306
Services billed
10,022

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide37$60,372
Xigduo XrDapaglifloz Propaned/Metformin37$49,674
MounjaroTirzepatide18$28,836
Tresiba Flextouch U-200Insulin Degludec11$21,606
Synjardy XrEmpagliflozin/Metformin Hcl15$21,190
EliquisApixaban14$21,118
JardianceEmpagliflozin13$20,587
SymbicortBudesonide/Formoterol Fumarate14$4,098
SynthroidLevothyroxine Sodium33$3,205
Levothyroxine Sodium221$2,443
Rosuvastatin Calcium228$2,217
Omeprazole144$2,154
Atorvastatin Calcium287$2,075
Pravastatin Sodium235$1,847
Valsartan59$1,633

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,316$60,37237 claims
Boehringer IngelheimSynjardy Xr, Jardiance$332$41,77628 claims
Lilly USA, LLCMounjaro$144$28,83618 claims
PfizerEliquis$131$21,11814 claims
AstraZenecaSymbicort$400$4,09814 claims
AbbVieSynthroid$538$3,20533 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Plano

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →